GlobeNewswire Inc.T3·15d ago
NUWE Nuwellis, Inc.
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
NUWE
—
—
What changed
Recent filings, trades and movesKey stats
Related
About
- Industry (SIC)
- ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS (3845) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 38
- List Date
- 2012-02-16
- CIK
- 0001506492
- Next Earnings
- 2026-11-12 (Pre-Market)
- EPS Forecast
- ($122.85)
- Headquarters
- Eden Prairie, MN
- Homepage
- https://www.nuwellis.com
Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -3.23% | -15.88% | -33.19% | 2.50% | 108.29% | 11.70% |
| Feb | -- | -16.30% | -8.17% | 26.01% | 3.31% | -60.78% | -11.19% |
| Mar | -- | 1.10% | -38.01% | -39.77% | -21.67% | -29.53% | -25.58% |
| Apr | -1.80% | -19.10% | 0.82% | -59.10% | 3.34% | 3.67% | -12.03% |
| May | -20.71% | -19.40% | -44.91% | 96.99% | -16.52% | -27.69% | -5.37% |
| Jun | -4.76% | -6.52% | -2.18% | -39.23% | -73.92% | -87.55% | -35.69% |
| Jul | -1.46% | -7.95% | -5.73% | -41.89% | -1.18% | -44.59% | -17.13% |
| Aug | -6.26% | 159.46% | -26.02% | -48.55% | -43.96% | -50.78% | -2.68% |
| Sep | -45.27% | -55.80% | -20.11% | -8.46% | -33.66% | -4.91% | -28.04% |
| Oct | -4.13% | -36.92% | -44.07% | 16.22% | -10.90% | -15.74% | -15.92% |
| Nov | -25.00% | -47.41% | -10.81% | -2.21% | -11.86% | 1.16%* | -16.02% |
| Dec | -21.38% | -29.47% | -4.16% | -15.91% | -27.50% | -- | -19.68% |
| Total | -78.81% | -87.67% | -93.07% | -93.51% | -96.10% | -98.81% | -91.33% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $4.92
SMA 50: $6.06
SMA 200: $203.87
Current: $5.43
EMA 12: $5.09
EMA 26: $5.47
MACD: -0.3735 | Signal: 0.1789
BEARISH
ADX (14): 13.98
RANGE
+DI: 33.61
−DI: 24.31
Momentum Oscillators
RSI (14): 49.08
NEUTRAL
Stoch %K: 57.91
Stoch %D: 52.49
Williams %R: -37.19
Volume & Volatility
BB Upper: $6.44
BB Lower: $3.39
NEUTRAL
OBV: 63,615,774
Vol SMA 20: 2,114,534
Vol ROC: -99.97%
ATR: $0.75
True Range: $0.25
HV 20: 272.9%
HV 30: 228.5%
HV 60: 184.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-13T00:00:00 – 2026-11-10T00:00:00
AI Analysis
Written before NUWE’s Aug 13 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report: NUWE
Executive Summary
Overall assessment: BEARISH with a confidence level of 7/10.
Key drivers: High volatility, bearish MACD signal, oversold RSI, and negative news sentiment.
Primary risks: High volatility, potential for further price decline if technical signals continue to deteriorate.
Investment thesis: The stock is trading in a downtrend, with recent news headlines highlighting the company's financial struggles. The high volatility and bearish momentum indicators suggest that the stock may continue to decline in the short term.
Recent news sentiment impact: The positive news headline from Nuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴) has a neutral impact on the overall analysis, as it does not significantly affect the bearish momentum indicators.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Downtrend; Medium-term (1-3 months): Downtrend; Long-term (3-12 months): Bearish consolidation
Support/Resistance Levels:
- Lower Bollinger Band: $2.16
- Middle Bollinger Band: $3.77
- Upper Bollinger Band: $5.38
- SMA 20: $3.77
- SMA 50: $19.03
- SMA 200: $63.43
Momentum Signals:
- RSI (14): 16.71 (oversold)
- MACD: -4.23 / Signal: 1.07 / Histogram: -5.30 (bearish)
- Bollinger Bands position: neutral
Volume Analysis: Volume trends suggest a potential reversal, but the on-balance volume (OBV) suggests that the stock may continue to decline.
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines highlight Nuwellis's financial struggles and lack of significant catalysts driving the stock price. The positive sentiment from the PC⁴ announcement is neutralized by the bearish momentum indicators.
Sentiment Assessment: Neutral, with a slight tilt towards negative due to the bearish MACD signal and oversold RSI.
Catalyst Identification: No near-term catalysts identified that could significantly impact the stock price.
Risk & Volatility Assessment
Beta Interpretation: High risk relative to market (beta >1.5).
Volatility Regime: Current volatility level is high, consistent with historical volatility data.
Options Market Signals: IV rank: 76.54; Put/call ratios: 0.92; Unusual activity: N/A
Downside Protection: Support levels at $2.16 and $3.77 may provide some protection against further price declines.
Market Context & Positioning
Sector Performance: Nuwellis is underperforming its sector, with a relative strength index (RSI) of 40.17.
Institutional Activity: Volume patterns suggest institutional interest, but the lack of significant buying pressure supports the bearish thesis.
Correlation Analysis: The stock has a low correlation coefficient with the market (R-squared interpretation), indicating that it may continue to decline independently of market trends.
Key Levels & Action Items
Critical Price Levels: Support at $2.16 and $3.77, resistance at $5.38.
Breakout/Breakdown Levels: Break below $2.16 could trigger further price declines, while a breakout above $5.38 may indicate a reversal.
Time-Sensitive Catalysts: No near-term catalysts identified that could significantly impact the stock price.
Risk Management: Stop-loss levels at $1.90 and $3.50, with position sizing considerations based on risk tolerance.
Note: This analysis is based on the provided data and does not constitute investment advice. It is essential to consider your individual risk tolerance, financial goals, and market conditions before making any investment decisions.
Generated
News
All NUWE news →
GlobeNewswire Inc.T3·2mo ago
GlobeNewswire Inc.T3·3mo ago
GlobeNewswire Inc.T3·4mo ago
BenzingaT3·5mo ago
GlobeNewswire Inc.T3·5mo ago
GlobeNewswire Inc.T3·6mo ago
BenzingaT3·7mo ago
BenzingaT3·9mo ago
BenzingaT3·14mo ago
Showing 1–10 of 50
Page 1 of 5
NUWE Options Activity & IV Rank
Loading options activity...
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 4.2724
Alpha: -328.45%
Correlation: 0.2567
R-Squared: 6.6%
Stock Volatility: 228.0%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 250
Period: 252 trading days
Data Points: 250
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
NUWE Institutional Ownership (13F)
Filings for 2026-06-30 · 4 already for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
NUWE Insider Trading (Form 4)
Latest: 2026-04-29Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-04-29 | Archelle Georgiou Feldshon | Director | Grant (A) | +6,744 opt | — | EDGAR | |
| 2026-04-29 | David McDonald | Director | Grant (A) | +6,744 opt | — | EDGAR | |
| 2026-04-29 | Martin J Emerson | Director | Grant (A) | +6,744 opt | — | EDGAR | |
| 2026-04-29 | Gregory D Waller | Director | Grant (A) | +6,744 opt | — | EDGAR | |
| 2025-07-01 | John L Erb | CEO and President | Grant (A) | +115,329 opt | — | EDGAR | |
| 2025-06-11 | John L Erb | CEO and President | Conv (C) | +1,100,022 | $0.06 | $66.0K | EDGAR |
| 2025-05-21 | Gregory D Waller | Director | Grant (A) | +17,496 opt | — | EDGAR | |
| 2025-05-21 | David McDonald | Director | Grant (A) | +17,496 opt | — | EDGAR | |
| 2025-05-21 | Michael Kendrick McCormick | Director | Grant (A) | +17,496 opt | — | EDGAR | |
| 2025-05-21 | Archelle Georgiou Feldshon | Director | Grant (A) | +17,496 opt | — | EDGAR | |
| 2024-01-04 | Michael Kendrick McCormick | Director | Grant (A) | +20,836 opt | — | EDGAR | |
| 2024-01-04 | David McDonald | Director | Grant (A) | +11,365 opt | — | EDGAR | |
| 2024-01-04 | Archelle Georgiou Feldshon | Director | Grant (A) | +11,365 opt | — | EDGAR | |
| 2023-09-06 | Robert Benjamin Scott | Chief Financial Officer | Grant (A) | +18,643 opt | — | EDGAR | |
| 2023-06-05 | Michael Kendrick McCormick | Director | Grant (A) | +1,967 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
NUWE Insider Holdings
1 insider · @ $5.24
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | John L Erb | CEO and President | 83 | $435 | $0 | 6 | 2025-07-01 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
NUWE Board & Officers
As of SEC filings through Jul 1, 2026Directors 4
- Gregory D Waller · since Feb 14, 2012
- Archelle Georgiou Feldshon · since Nov 1, 2023
- David McDonald · since Nov 1, 2023
- Martin J Emerson · since Feb 24, 2026
Officers 2
- Michael Kendrick McCormick · President and CEO · listed since Jul 2026
- Carisa Schultz · Chief Financial Officer · since Jan 28, 2026
10% owners 1
- John L Erb · listed since Jun 2025
Changes in the last 10 years (35)
| Jul 1, 2026 | Michael Kendrick McCormick first listed as President and CEO in an SEC filing |
| Jun 16, 2026 | The company announced the departure of John L Erb from the board in an SEC filing |
| Jun 16, 2026 | The company announced the departure of John L Erb as CEO and President in an SEC filing |
| Jun 16, 2026 | The company announced the departure of John L Erb as CEO and President in an SEC filing |
| Mar 26, 2026 | The company announced the departure of Mika Grasso from the board in an SEC filing |
| Mar 26, 2026 | The company announced the departure of Katharyn Field from the board in an SEC filing |
| Feb 24, 2026 | Martin J Emerson became a director |
| Jan 28, 2026 | Carisa Schultz became Chief Financial Officer |
| Jan 21, 2026 | The company announced the departure of Michael Kendrick McCormick from the board in an SEC filing |
| Jan 21, 2026 | Mika Grasso became a director |
| Jan 21, 2026 | Katharyn Field became a director |
| Jun 11, 2025 | John L Erb first listed as a 10% owner in an SEC filing |
| Jun 11, 2025 | John L Erb first listed as CEO and President in an SEC filing |
| Nov 1, 2023 | David McDonald became a director |
| Nov 1, 2023 | Archelle Georgiou Feldshon became a director |
| Oct 31, 2023 | The company announced the departure of Jon W Salveson from the board in an SEC filing |
| Sep 2, 2023 | Robert Benjamin Scott became Chief Financial Officer |
| Aug 4, 2023 | The company announced the departure of Lynn Larson Blake as Chief Financial Officer in an SEC filing |
| Jun 2, 2023 | The company announced the departure of Warren S Watson from the board in an SEC filing |
| Jun 1, 2023 | Michael Kendrick McCormick became a director |
| Jan 16, 2023 | The company announced the departure of Steven Frank Brandt from the board in an SEC filing |
| Oct 19, 2022 | Lynn Larson Blake became Chief Financial Officer |
| Sep 19, 2022 | The company announced the departure of George Montague as CFO and Treasurer in an SEC filing |
| Jun 28, 2021 | George Montague became CFO and Treasurer |
| Jun 7, 2021 | Neil P Ayotte became SVP, Secretary, GC & CCO |
| May 20, 2021 | Nestor Jaramillo Jr. listed as President and CEO (previously Chief Commercial Officer) in SEC filings |
| May 20, 2021 | Nestor Jaramillo Jr. first listed as a director in an SEC filing |
| Apr 16, 2021 | Paul Wotta became Principal Accounting Officer |
| May 20, 2020 | Thomas P. Lynch became Chief Legal/Compliance Officer |
| Sep 3, 2019 | Maria Rosa Costanzo became a director |
| May 7, 2019 | Nestor Jaramillo Jr. became Chief Commercial Officer |
| Apr 24, 2017 | Jim Breidenstein became Chief Commercial Officer |
| Apr 19, 2017 | Ki Yong Choi became a 10% owner |
| Feb 2, 2017 | Steven Frank Brandt became a director |
| Feb 2, 2017 | Matthew E. Likens became a director |
Not reported recently (12)
- David A Rosa · Last reported as a director in an SEC filing dated Jun 6, 2024
- Maria Rosa Costanzo · Last reported as a director in an SEC filing dated Jun 6, 2024
- Robert Benjamin Scott · Last reported as Chief Financial Officer in an SEC filing dated Sep 6, 2023
- Nestor Jaramillo Jr. · Last reported as a director in an SEC filing dated May 19, 2023
- Neil P Ayotte · Last reported as SVP, Secretary, GC & CCO in an SEC filing dated Mar 7, 2023
- Paul Wotta · Last reported as Principal Accounting Officer in an SEC filing dated Apr 16, 2021
- Claudia Drayton · Last reported as Chief Financial Officer in an SEC filing dated Jan 26, 2021
- Thomas P. Lynch · Last reported as Chief Legal/Compliance Officer in an SEC filing dated Jan 26, 2021
- Matthew E. Likens · Last reported as a director in an SEC filing dated May 28, 2019
- Jim Breidenstein · Last reported as Chief Commercial Officer in an SEC filing dated Jan 5, 2018
- Ki Yong Choi · Last reported as a 10% owner in an SEC filing dated Oct 13, 2017
- Molly Wade · Last reported as Vice President in an SEC filing dated Jan 17, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-10-23
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-10-23 | Shareholder rights change · Bylaws or fiscal year change | EDGAR |
| 2026-08-26 | Regulation FD disclosure | EDGAR |
| 2026-08-13 | Earnings results | EDGAR |
| 2026-08-03 | Material agreement · Unregistered share sale · Other events | EDGAR |
| 2026-07-24 | Shareholder vote results | EDGAR |
| 2026-06-24 | Shareholder rights change · Bylaws or fiscal year change | EDGAR |
| 2026-06-18 | Director or officer change · Regulation FD disclosure | EDGAR |
| 2026-06-10 | Regulation FD disclosure | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-08-13 | 0001140361-26-032810 | EDGAR |
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
NUWE vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| MDT Medtronic plc | $131.5B | 24.6 | +9.8% | +4.4% | 47 |
| MASI Masimo Corporation | $9.4B | 128.5 | +9.2% | +41.2% | — |
| LIVN LivaNova PLC Ordinary Shares | $5.1B | 30.1 | +11.7% | +49.2% | 45 |
| ITGR Integer Holdings Corporation | $4.3B | 43.5 | −0.3% | +64.9% | 6 |
| TMDX TransMedics Group, Inc. Common Stock | $3.3B | 24.0 | +25.8% | −24.6% | 14 |
| AXGN Axogen, Inc. Common Stock | $3.0B | — | +24.3% | +66.5% | 11 |
| BLFS BioLife Solutions Inc. | $1.9B | 33.0 | +25.4% | +61.6% | — |
| CNMD CONMED Corporation | $1.5B | 21.1 | +1.6% | +25.3% | 31 |
| NUWE Nuwellis, Inc. Common Stock | $2M | — | — | −99.0% | — |
| Peer median | $3.8B | 30.1 | +10.8% | +45.2% | 22 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.